Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide-based HIV post-exposure prophylaxis study
ChiCTR1900022881Phase 4Recruiting
- Sponsor
- Chongqing Public Health Medical Treatment Center
- Start
- May 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of albuvirtide, dolutegravir, tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Chongqing Public Health Medical Treatment Center. Primary endpoint: Proportion of patients taking uninterrupted HIV post-exposure prophylaxis for 28 days. Started May 2019; status: recruiting.
02
Drugs
albuvirtidedolutegravirtenofovir disoproxil fumaratelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1900022881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022881.